The CFO of OptimizeRx Corporation (Other OTC: OPRX) is Buying Shares

By Carrie Williams

Today, the CFO of OptimizeRx Corporation (Other OTC: OPRX), Douglas Baker, bought shares of OPRX for $47.25K.

Following this transaction Douglas Baker’s holding in the company was increased by 126.22% to a total of $272.6K. Following Douglas Baker’s last OPRX Buy transaction on May 15, 2017, the stock climbed by 7.9%.

See today’s analyst top recommended stocks >>

Based on OptimizeRx Corporation’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $5.1 million and quarterly net profit of $280.5K. In comparison, last year the company earned revenue of $2.87 million and had a GAAP net loss of $361.5K. Currently, OptimizeRx Corporation has an average volume of 199.3K. The Company has a Price to Book ratio of 8.8066.

Starting in June 2018, OPRX received 4 Buy ratings in a row.

In the last 30 days, insiders have sold $57.47K worth of OPRX shares and purchased $47.25K worth of OPRX shares. The insider sentiment on OptimizeRx Corporation has been positive according to 16 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OptimizeRx Corp. engages in the provision of digital health messaging via electronic health records (EHR), which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. Its services include EHR workflow solutions such as financial messaging, patient education, and brand messaging; and brand support.